The MAPT gene (Microtubule-Associated Protein Tau) encodes the tau protein, a critical microtubule-stabilizing protein expressed primarily in neurons. Located on chromosome 17q21.31, MAPT is essential for axonal transport and neuronal viability. Pathological mutations and dysregulation of MAPT lead to tau aggregation in neurodegenerative diseases collectively termed tauopathies, including Alzheimer's disease, frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and primary age-related tauopathy (PART)[@ballard2011].
The MAPT gene spans approximately 150 kb on the long arm of chromosome 17 at position 17q21.31. This region is notable for its complex genomic architecture, including a ~900 kb inversion that creates two distinct haplotypes (H1 and H2) in European populations. The H1 haplotype is associated with increased risk for several tauopathies, including PSP and CBD[@connor2009].
The MAPT gene consists of 16 exons, with alternative splicing producing multiple transcript variants. The central region containing exons 2, 3, and 10 undergoes tissue-specific and developmentally regulated splicing, generating six major isoforms in the adult human brain. Exon 10 encodes the second microtubule-binding repeat, and mutations affecting its splicing are particularly relevant to disease pathogenesis[@andreadis2006].
| Exon | Size (bp) | Function |
|---|---|---|
| 1 | 129 | 5'UTR and start codon |
| 2 | 108 | N-terminal projection domain |
| 3 | 108 | N-terminal projection domain |
| 4-9 | Variable | Encodes N-terminal region |
| 10 | 93 | Microtubule-binding repeat 2 |
| 11-13 | Variable | Microtubule-binding repeats 3-4 |
| 14-16 | Variable | 3'UTR |
The tau protein is produced in six isoforms ranging from 352 to 441 amino acids, differing by the inclusion of zero, one, or two N-terminal inserts (from exons 2 and 3) and three or four microtubule-binding repeats (from exon 10). The isoforms are:
The 4R isoforms (containing exon 10) bind microtubules more avidly than 3R isoforms and are predominant in adult brain. The balance between 3R and 4R tau is critical—imbalances contribute to pathology in several tauopathies[@goedert2006].
Tau protein contains several functional domains:
The primary physiological function of tau is to bind and stabilize microtubules, essential for axonal transport and neuronal polarity. Tau promotes microtubule polymerization by reducing the critical concentration of tubulin required for assembly and by increasing the rate of microtubule nucleation. The microtubule-binding repeats (especially R2 and R3) interact with tubulin dimers, while the N-terminal domain projects outward, maintaining proper spacing between microtubules in axons[@baas2013].
By stabilizing microtubules, tau indirectly supports axonal transport of organelles, vesicles, and proteins via motor proteins kinesin and dynein. The binding affinity of tau for microtubules is modulated by phosphorylation—hyperphosphorylation reduces binding, releasing tau from microtubules and impairing axonal transport, a well-documented early event in neurodegeneration[@stamer2002].
Emerging evidence indicates tau localizes to synapses where it may have roles in synaptic plasticity, mitochondrial trafficking, and neuronal signaling. Tau knockout mice show altered synaptic plasticity and memory deficits, suggesting functions beyond microtubule stabilization. Additionally, tau can be secreted in activity-dependent manner, potentially serving as a propagation vector in tauopathies[@pooler2013].
In Alzheimer's disease (AD), tau becomes abnormally hyperphosphorylated, leading to its aggregation into paired helical filaments (PHFs) and straight filaments, which form neurofibrillary tangles (NFTs). The density of NFTs correlates strongly with cognitive decline. Hyperphosphorylation of tau is driven by失调 of multiple kinases (GSK3β, CDK5, MARK, DYRK1A) and phosphatases (PP2A). NFT progression follows a predictable anatomical pattern: entorhinal cortex → hippocampus → limbic system → isocortex, corresponding to clinical staging of dementia[@braak1995].
Key phosphorylation sites implicated in AD include:
FTDP-17 is caused by autosomal dominant mutations in MAPT, with over 50 pathogenic variants identified. These mutations either:
The most common mutation, P301L, reduces microtubule binding ~4-fold and promotes aggregation. Splicing mutations shift the 3R/4R ratio toward 4R tau, which aggregates more readily[@hutton1998].
PSP is strongly associated with the H1 haplotype of MAPT. While no pathogenic mutations cause PSP, the H1 haplotype contains polymorphisms that increase expression of 4R tau isoforms. The H1c sub-haplotype shows strongest association. PSP is characterized by accumulation of 4R tau in globose neurofibrillary tangles and tau-positive tufted astrocytes, primarily affecting the basal ganglia, brainstem, and cerebellar nuclei[@williams2007].
CBD is another 4R tauopathy associated with MAPT H1 haplotype. Pathological tau in CBD forms astrocytic plaques and corticobasal balloons, with 4R tau predominating. The relationship between MAPT variants and CBD is complex, with both shared and distinct genetic risk factors compared to PSP[@ghetti2015].
PART is characterized by NFT pathology primarily in the medial temporal lobe (hippocampus, entorhinal cortex) in the absence of significant amyloid plaques. The relationship between MAPT and PART is still being characterized, though some evidence suggests specific haplotypes may influence susceptibility[@crary2014].
Over 50 pathogenic mutations in MAPT cause FTDP-17 and related tauopathies. These mutations are inherited in autosomal dominant fashion with high penetrance. Key mutation hotspots include:
| Mutation | Effect | Disease Association |
|---|---|---|
| P301L | ↓ microtubule binding, ↑ aggregation | FTDP-17, CBD |
| P301S | ↓ microtubule binding, ↑ aggregation | FTDP-17 |
| K257T | ↓ microtubule binding | FTDP-17 |
| G272V | ↓ microtubule binding | FTDP-17 |
| R406W | ↑ aggregation, altered binding | FTDP-17 |
| ΔN296 | Alters splicing → 4R | FTDP-17 |
| N279K | Alters splicing → 4R | FTDP-17 |
| S305S | Alters splicing → 4R | FTDP-17 |
The MAPT region contains two major haplotypes:
The H1 haplotype is in linkage disequilibrium with multiple polymorphisms that affect tau expression and splicing, contributing to increased disease risk[@allen2012].
Multiple therapeutic approaches targeting tau are in development:
Several candidates have reached clinical trials, though efficacy has been limited to date[@delenclos2019].
Multiple kinases phosphorylate tau at disease-relevant sites:
The main phosphatase regulating tau phosphorylation state is PP2A (Protein Phosphatase 2A), which accounts for ~70% of tau phosphatase activity. PP2A activity is reduced in AD brains, contributing to hyperphosphorylation[@gong2004].
Tau interacts with numerous proteins:
Transgenic mice expressing human MAPT mutations reproduce key features of tauopathy:
These models have been instrumental in understanding tau pathogenesis and testing therapeutics[@vanle2019].
Cerebrospinal fluid (CSF) tau levels are elevated in AD:
Plasma p-tau217 and p-tau181 have emerged as highly accurate biomarkers for AD diagnosis and are being used in clinical trials to select patients and monitor treatment response[@schindler2020].
Tau PET ligands (e.g., flortaucipir, MK-6240) allow in vivo visualization of tau pathology, providing valuable biomarkers for disease staging and treatment monitoring. Tau PET signal correlates with cognitive impairment and predicts progression[@schll2017].
The MAPT promoter contains CpG islands that undergo methylation changes in aging and AD brains. Altered DNA methylation at the MAPT locus may influence gene expression and disease risk. Studies have shown hypomethylation at specific MAPT promoter regions in AD brains, potentially contributing to altered tau expression patterns. The relationship between MAPT methylation and tau pathology remains an active area of investigation[@iwata2015].
Histone acetylation and methylation at the MAPT locus can influence transcription. HDAC (Histone Deacetylase) inhibitors have been shown to modulate MAPT expression in cellular models. The balance between histone acetylation and deacetylation may be relevant to tauopathy pathogenesis, though therapeutic targeting remains experimental[@routtenberg2015].
MicroRNAs (miRNAs) regulate MAPT expression post-transcriptionally:
Dysregulation of these miRNAs has been implicated in AD and other tauopathies. Some miRNAs show promise as biomarkers and potential therapeutic targets[@he2015].
Tau phosphorylation is the best-characterized post-translational modification and is central to tau pathology. Over 85 potential phosphorylation sites have been identified on tau, with site-specific phosphorylation affecting different aspects of tau function. The balance between kinases and phosphatases determines phosphorylation state:
Kinase hyperactivity: GSK3β, CDK5, MARK, and DYRK1A are all upregulated or hyperactive in AD brains
Phosphatase deficiency: PP2A activity is reduced by up to 50% in AD brains
Phosphorylation at different sites has distinct consequences:
Tau can be modified by O-linked N-acetylglucosamine (O-GlcNAc) on serine and threonine residues. This modification is reduced in AD brains and can compete with phosphorylation. O-GlcNAcylation may protect tau from aggregation, and enhancing this modification is being explored therapeutically[@liu2009].
Tau acetylation at lysine residues (particularly K280, K369) promotes aggregation and reduces microtubule binding. Histone acetyltransferase p300 can acetylate tau, while deacetylases SIRT1 can remove these modifications. Acetylation is a potential therapeutic target[@min2010].
Tau can be ubiquitinated for degradation by the proteasome. In AD, tau shows abnormal ubiquitination patterns. SUMOylation (Small Ubiquitin-like Modifier) can modulate tau aggregation and is altered in tauopathies. The balance between different post-translational modifications determines tau's fate[@tai2012].
Tau can be cleaved by multiple proteases:
Truncated tau is more aggregation-prone and is found in brain tissue from AD and FTDP-17 patients[@rohn2008].
Before forming insoluble aggregates, tau forms soluble oligomers that are highly toxic. These oligomers may be the primary neurotoxic species, and they can propagate between cells in a prion-like manner. Tau oligomers:
Tau pathology spreads in a predictable pattern through connected neural networks. The "prion-like" spread hypothesis suggests that pathological tau can be taken up by neighboring neurons and template the conversion of normal tau to the pathological form. This spread may explain the progression of tau pathology from entorhinal cortex to distant brain regions[@guo2011].
Tau can be released from neurons through:
Once outside the cell, tau can be internalized by neighboring neurons through various mechanisms, including macropinocytosis and receptor-mediated endocytosis. The spread of tau pathology is a key therapeutic target[@frost2009].
Active immunization: Aducanumab (approved for AD) targets amyloid, but anti-tau vaccines have shown promise in preclinical models. ACI-35 (a liposome-based anti-phospho-tau vaccine) has completed Phase 1 trials showing safety and immunogenicity[@boutajangout2010].
Passive immunization: Several anti-tau antibodies are in development:
These antibodies aim to clear extracellular tau and prevent spread.
Tau aggregation inhibitors: Methylene blue derivatives (e.g., leuco-methylthioninium) have shown some efficacy in clinical trials but with mixed results. Other aggregation inhibitors are in development[@wischik2015].
Kinase inhibitors: GSK3β inhibitors (e.g., tideglusib) have been tested in clinical trials with limited success. CDK5 inhibitors remain in preclinical development.
Microtubule stabilizers: Paclitaxel and Davunetide have been tested but face challenges with brain penetration.
Antisense oligonucleotides (ASOs) targeting MAPT mRNA can reduce tau expression in preclinical models. Ionis Pharmaceuticals has developed ASOs that reduce tau in Phase 1 trials. CRISPR-based approaches for allele-specific silencing of mutant MAPT are being explored[@devos2017].
Transgenic and knock-in mouse models have provided critical insights:
| Model | Mutation | Key Features |
|---|---|---|
| JNPL3 | P301L | Age-dependent NFT formation, motor deficits |
| rTg4510 | P301L (inducible) | Reversible tau expression, cognitive decline |
| hTau | Human MAPT (no mouse) | Pure human tau expression |
| P301S | P301S | Rapid onset, severe pathology |
| K257I | K257I | Impaired microtubule binding |
Non-human primate models and iPSC-derived neurons are increasingly used for therapeutic testing[@duyckaerts2008].
While disease-modifying therapies remain elusive, clinical management focuses on:
Genetic counseling is important for families with FTDP-17 mutations.
Key research priorities include:
The complexity of tau biology presents challenges but also opportunities for multi-target therapeutic approaches[@bloom2014].
MAPT (Microtubule-Associated Protein Tau) expression patterns:
MAPT is expressed in:
| Region | Expression Level | Data Source |
|---|---|---|
| Hippocampus (CA1) | Very High | Human MTG |
| Prefrontal Cortex | High | Allen Human Brain Atlas |
| Temporal Cortex | High | Allen Human Brain Atlas |
| Parietal Cortex | High | Allen Human Brain Atlas |
| Locus Coeruleus | High | Human MTG |
| Cerebellum | Low-Moderate | Allen Human Brain Atlas |